Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics. (PubMed, Curr Issues Mol Biol) - "Although biologic agents such as dupilumab, tralokinumab, and lebrikizumab have revolutionized AD management, their high costs, injectable administration, and limited global accessibility highlight the need for alternative options...This review provides a comprehensive analysis of key agents including Janus kinase (JAK) inhibitors (upadacitinib, abrocitinib, baricitinib, ruxolitinib, delgocitinib), phosphodiesterase 4 (PDE4) inhibitors (crisaborole, difamilast, roflumilast, apremilast), as well as STAT6 degraders (KT621, NX3911), aryl hydrocarbon receptor modulators, histamine H4 receptor antagonists (adriforant, izuforant), and sphingosine-1-phosphate receptor modulators (etrasimod, BMS-986166). We summarize their mechanisms of action, pharmacological profiles, and pivotal clinical trial data, emphasizing their potential to address unmet therapeutic needs. Finally, we discuss safety concerns, long-term tolerability, and future directions for integrating small molecule..."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • STAT6

Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort. (PubMed, Acta Derm Venereol) - "This study aimed to describe the drug survival, with associated predictors, of treatment with abrocitinib, baricitinib, cyclosporine, dupilumab, methotrexate, tralokinumab, and upadacitinib among patients with atopic dermatitis in Sweden who were recruited into the multicentre prospective SwedAD cohort between January 2017 and April 2024. In conclusion, dupilumab therapy demonstrated longer drug survival than methotrexate in atopic dermatitis. The impact of national treatment guidelines and time since drug approval should be considered when interpreting the results."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Molecular Signatures in Inflammatory Skin Disease (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Prof. Dr. Stephan Weidinger | Trial completion date: Dec 2028 ➔ Dec 2029 | Trial primary completion date: Dec 2027 ➔ Dec 2028

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Oncology • Psoriasis

Effectiveness of tralokinumab and lebrikizumab in Japanese atopic dermatitis patients with persistent head and neck dermatitis after long-term treatment with dupilumab: A single-centerretrospective study (EADV 2025) - No abstract available

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Conjunctivitis secondary to novel systemic dermatologic agents: a growing concern. (PubMed, Curr Opin Ophthalmol) - "With the expanding use of novel systemic dermatologic therapies, ocular surface complications have become an important concern. Multidisciplinary collaboration and increased awareness are vital to prevent vision-threatening outcomes. Ongoing research is needed to elucidate pathophysiology and optimize therapeutic approaches that balance effective skin disease control with ocular health."

Journal • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Psoriasis

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study. (PubMed, Int J Dermatol) - "Conjunctivitis represents a relatively frequent AE in patients with AD receiving dupilumab or tralokinumab. However, earlier onset of conjunctivitis with tralokinumab and higher discontinuation rates with dupilumab suggest differing tolerability profiles. Early recognition of ocular symptoms is essential, and dermatologists should promptly initiate supportive eye care and refer to ophthalmologists when appropriate to avoid unnecessary treatment interruptions."

Journal • Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

Effectiveness and safety of dupilumab versus tralokinumab in atopic dermatitis: A propensity score– matched analysis from the BioDay registry (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action. (PubMed, J Invest Dermatol) - "It describes the structural and thermodynamic properties of IL-4/IL-13 signaling and how these properties inform MOA differences between the AD biologics dupilumab, tralokinumab, lebrikizumab, and rademikibart and translates the molecular science into potential clinical implications of these MOA differences. The fundamental conclusion is that each of the biologics currently in clinical use for treating AD function very uniquely by disrupting the assembly of the cytokine-receptor signaling complex at different energetic steps."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IFNG • IL13 • IL22 • IL4 • TSLP

Letter: Long-Term Effectiveness of Tralokinumab in Patients With Atopic Dermatitis Refractory to Dupilumab: A 48-Week Real-World Study. (PubMed, Dermatitis) - No abstract available

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: Results from a Multicentre, Observational, Retrospective Study (EADV 2025) - No abstract available

Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology

ADHAND: A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (clinicaltrials.gov) - P3 | N=235 | Active, not recruiting | Sponsor: LEO Pharma | Recruiting ➔ Active, not recruiting | N=402 ➔ 235

Enrollment change • Enrollment closed • Monotherapy • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials. (PubMed, Br J Dermatol) - P2, P3 | "Long-term use of tralokinumab in adults and adolescents with moderate-to-severe AD was well-tolerated and consistent with the initial placebo-controlled treatment period, with no new safety signals identified."

Journal • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases

Impact Of Tralokinumab On Circulating And Skin Immune Cell landscape In Patients With Atopic Dermatitis (ESDR 2025) - No abstract available

Clinical • Immune cell • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-World Clinical Practice Evaluation of Tralokinumab in Atopic Dermatitis: A 52-Week Multi-Center Retrospective Study in the Basque Country. (PubMed, J Clin Med) - " Our findings support tralokinumab as a safe and effective long-term therapy for AD in routine practice. Results were consistent with, or superior to, pivotal and other RWE studies."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • IL13

Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data. (PubMed, Front Immunol) - "Patients received JAK1i (n=37; abrocitinib, n=16; upadacitinib, n=21) or IL-13Ab (n=38; lebrikizumab, n=21; tralokinumab, n=17). Eosinophil count reduction was the most reflective biomarker of JAK1i efficacy, potentially due to IL-5 suppression, whereas TARC improvement was significantly associated with patients' treatment response to IL-13Ab. These findings highlight the need for further long-term studies."

Biomarker • Clinical • Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13 • IL5

Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications. (PubMed, Pharmaceuticals (Basel)) - "Monoclonal antibodies targeting IgE (omalizumab) and IL-5 (mepolizumab, benralizumab, reslizumab, depemokimab) have demonstrated the ability to reduce exacerbation frequency and improve lung function, with newer agents such as depemokimab offering extended dosing intervals. Itepekimab, an anti-IL-33 antibody, effectively engages its target and mitigates tissue eosinophilia, while CM310-stapokibart, tralokinumab, and lebrikizumab inhibit IL-4/IL-13 signaling with variable efficacy depending on patient biomarkers. Comparative analyses of these biologics, encompassing affinity, dosing regimens, and trial outcomes, underscore the imperative of personalized therapy to optimize disease control in severe asthma."

Biomarker • Journal • Review • Asthma • Eosinophilia • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL13 • IL17A • IL33 • IL4 • IL5

Rapid response and sustained remission of Hailey-Hailey disease under IL-13 inhibition with tralokinumab (EADV 2025) - No abstract available

Clinical • Genetic Disorders • IL13

Effect of tralokinumab on QoL in atopic patients with head and neck involvement (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Long-term efficacy with tralokinumab in patients with moderate-to-severe atopic dermatitis: final results from the 5-year ECZTEND study (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA). (PubMed, Dermatol Ther (Heidelb)) - P3 | "Tralokinumab formulated as a pre-filled pen was effective, well tolerated, and easy to use. The tralokinumab pre-filled pen may offer a more convenient method of tralokinumab administration with fewer injections per dose."

Journal • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness and safety of 12-months tralokinumab treatment in 824 adults with atopic dermatitis: Final real-world data from the prospective, non-interventional, international, single-cohort TRACE study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Recalcitrant Atopic Dermatitis: Switch from Tralokinumab to Lebrikizumab (EADV 2025) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

LEO Pharma Delivers 7% Revenue Growth at CER in H1 2025 and Achieves Key Milestones Enabling Future Growth (Businesswire) - "Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza/Adbry and Anzupgo, which combined had a revenue increase of 51% (CER). Sales in the Critical Care portfolio (formerly called ‘Thrombosis’) declined by 3% (CER) year-on-year, affected by the reversal of sales discounts in the same period last year."

Commercial • Atopic Dermatitis • Dermatology

Effectiveness of 12-months tralokinumab treatment in 654 adults with atopic dermatitis with head & neck area involvement: Final real-world data from the prospective, non-interventional, international, single-cohort TRACE study (EADV 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes (EADV 2025) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology